China Resources Pharmaceutical Group (3320.HK) Earnings Analysis

China Resources Pharmaceutical Group (3320.HK) next reports earnings on 2026-08-25, consensus EPS 0.4618 HKD. Last quarter (2026-03-24) it beat with EPS 0.345 HKD vs 0.2226 HKD est (+55%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E 6.85.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 3320.HK next report earnings?

Next earnings date2026-08-25
Consensus EPS estimate0.4618 HKD
Revenue estimate159.99B

3320.HK earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-240.345 HKD0.2226 HKD+55%Beat
2025-08-260.3623 HKD0.4195 HKD-13.6%Miss
2024-10-240.4493 HKD0.4605 HKD-2.4%Miss

Beat rate: 1/3 (33%) over reported quarters with consensus data.

3320.HK valuation and analyst view

Trailing P/E6.85
Trailing EPS0.71118 HKD
Price / book0.53
Dividend yield4.48%
Market cap30.03B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is China Resources Pharmaceutical Group (3320.HK)'s next earnings date?

China Resources Pharmaceutical Group is next scheduled to report on 2026-08-25, with a consensus EPS estimate of 0.4618 HKD and revenue estimate of 159.99B.

Did 3320.HK beat earnings last quarter?

In its 2026-03-24 report, 3320.HK posted EPS of 0.345 HKD versus a 0.2226 HKD estimate — a beat of 55%.

What is 3320.HK's earnings track record?

Over the last 3 reported quarters with consensus data, 3320.HK beat estimates 1 times (33%).

What is 3320.HK's current P/E ratio and EPS?

3320.HK trades at a trailing P/E of 6.85 on trailing EPS of 0.711179122916265 HKD.

What do analysts rate 3320.HK?

3320.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.